Cohere Health Vendor Deep Dive: The Complete RCM Prior Auth Platform Review (2026)

Cohere Health built its platform on a simple but correct bet: prior authorization is not an administrative problem — it's a clinical decision-making problem being solved with fax machines and phone calls. Six years and $200 million later, they're processing 12 million auth requests a year for 600,000 providers, auto-approving 90% of them with AI. The question for RCM leaders isn't whether the platform works. It's whether the tradeoffs fit your operation.

What Cohere Health Actually Does

Cohere Health sits at the intersection of health plan utilization management and provider prior authorization workflows. That's a meaningful distinction from most PA vendors, which are pure provider-side tools that help practices submit auths faster. Cohere's platform is deployed on the payer side — health plans use Cohere to transform how they manage utilization review, then surface the benefit to providers through streamlined submission and real-time clinical decision support.

The core mechanic: when a provider submits a prior auth request through Cohere's platform, the AI evaluates the clinical evidence against Cohere's clinician-built guidelines and either auto-approves, auto-pends for review, or flags for human clinical review. Up to 90% of requests are auto-approved without human intervention. The remaining 10% — the genuinely complex cases — get escalated to a clinician reviewer, but with a complete clinical picture already assembled by the AI.

What this means operationally: the speed advantage is real. Turnaround times compress from days to minutes on auto-approved cases. Provider abrasion drops because the fax-and-phone process is largely eliminated. And health plans maintain appropriate utilization oversight — Cohere isn't just approving everything, it's applying evidence-based clinical criteria to sort routine from complex.

The business model is health plan-facing. Cohere contracts with the payer, who deploys the platform and makes it available to their provider network. If your payer is on Cohere, you as a provider interact with their submission portal; if they're not, the platform is invisible to you. That's the most important context for any RCM leader evaluating this space.

Products & Platform

Cohere Unify™

The core platform — the operating system that powers everything else. Cohere Unify handles payer-provider collaboration on utilization management: clinical decision support, prior authorization workflows, real-time performance data, and provider engagement. It personalizes the submission experience based on provider behavior — a high-performing orthopedic group with a clean authorization history gets a different experience than a provider with a pattern of inappropriate utilization. This isn't gold carding (blanket exemptions) — it's dynamic clinical workflows that adapt based on evidence.

Cohere Align™

Launched March 2025. Align is Cohere's answer to the gold carding problem — health plans want to reduce provider abrasion without just blanket-exempting providers from authorization requirements. Align uses advanced analytics to identify which providers can handle expedited pathways and which need standard clinical review, then continuously optimizes those workflows as utilization patterns evolve. The pitch: 80% reduction in unnecessary authorizations for qualifying providers, without sacrificing oversight on cases where it matters.

Cohere Validate™ (Payment Integrity Suite)

The newest addition, launched October 2025 after Cohere's acquisition of ZignaAI in September 2025. Cohere Validate is an AI-powered near-real-time clinical and coding validation solution — applying the same clinical intelligence that Cohere brings to pre-auth to the payment integrity workflow. This is Cohere's "shift right" from pre-care decisions into post-care claim accuracy. For health plans already on Cohere for PA, this extends the clinical AI layer into payment integrity without a separate vendor relationship.

AI Capabilities — Real vs. Marketing

Cohere's AI story holds up under scrutiny better than most. Three things make it credible:

Clinician-led model development. Cohere doesn't use off-the-shelf clinical criteria — they build evidence-based guidelines in-house with clinical staff, then train their AI on those guidelines. The result is a model that reflects actual clinical best practices, not an algorithm optimizing for claim denials. This is the core differentiator versus pure AI vendors who are pattern-matching on claims data without clinical logic.

Scale feedback loop. 12 million prior auth requests per year generates a training dataset that competitors can't match. Every request — approved, pended, overturned on appeal — feeds back into the model. The AI is getting measurably better in ways that a vendor processing 500K auths a year can't replicate.

Responsible AI architecture. Cohere publishes its position that clinical expertise remains at the core of every decision. The 10% of cases that go to human review aren't random — the model is actively calibrated to identify cases where human clinical judgment is appropriate. That matters for payers managing risk and for regulatory compliance as CMS scrutiny of AI-driven PA increases.

What it doesn't do: Cohere is not a coding AI, not a CDI tool, and not an AR management platform. Their AI is entirely focused on the clinical decision layer of utilization management. Don't evaluate it as a broad RCM technology — it's a deep specialist.

Regulatory Tailwind — Why Now Matters

Cohere's timing is not accidental. CMS-0057-F (the Interoperability and Prior Authorization Final Rule) requires health plans to implement FHIR-based electronic PA APIs, with full implementation mandated by January 1, 2027. Reporting requirements were effective January 1, 2026. Every major commercial and Medicare Advantage payer is now legally required to modernize PA infrastructure on a hard deadline.

That regulatory forcing function is Cohere's most powerful sales tailwind. Health plans that have been slow-rolling digital PA transformation now have a compliance mandate. Cohere is positioned to be the platform they deploy to meet that mandate — with the added benefit that it improves clinical decision-making and reduces administrative costs at the same time.

The AMA has reported that 94% of physicians say PA delays care. CMS's own data shows PA-related delays correlate with adverse outcomes and increased downstream utilization. The regulatory pressure to fix this is bipartisan and building. Cohere is the infrastructure play for payers who need to modernize fast.

Who It's Built For

Health plans and Medicare Advantage organizations are the primary buyer. If you're a VP of Medical Management or Chief Medical Officer at a regional or national health plan, Cohere is a direct answer to your utilization management modernization problem.

Risk-bearing providers and IDNs with delegated utilization management are also a fit — if you've taken on capitation or full-risk contracts and are managing your own UM, Cohere's platform applies to your internal clinical review workflows.

Provider organizations benefit indirectly — if your payers deploy Cohere, your auth submission experience improves significantly. But providers don't buy Cohere directly. If you're a billing director or RCM leader, your leverage is knowing which of your payers are on Cohere (or evaluating it) and using that in contract conversations.

Cohere is less relevant for:

• Pure fee-for-service providers with no payers on the platform — you're invisible to their product
• Small practices — the platform is enterprise-grade and the implementation overhead reflects that
• Organizations looking for end-to-end RCM outsourcing — Cohere is clinical intelligence infrastructure, not an outsourced AR team

Pricing

Cohere does not publish pricing. Health plan contracts are typically structured as PMPM (per member per month) or per-authorization fees, scaled to plan membership and auth volume. The per-auth economics improve significantly at scale — a plan processing 1 million auths per year has very different unit economics than one processing 100K.

What to model: the ROI case for health plans is built on reduced administrative cost per authorization, faster turnaround, and downstream utilization improvements. Geisinger Health Plan's published results — 15% reduction in total medical expenses, 63% cut in PA denials — are the benchmark case study. Those numbers are real but represent an optimized deployment; expect a ramp period.

Integrations

Cohere integrates with major EHR platforms including Epic, Oracle Health (Cerner), and Meditech through HL7 FHIR-based APIs — which aligns with the CMS-0057-F mandate for electronic PA. Provider submissions can flow directly from the EHR into Cohere's platform without manual portal entry for connected systems.

Availity is a key distribution channel — Cohere's platform is accessible through Availity's provider portal, which is how a large portion of the provider community already manages PA workflows. That reduces the provider-side change management burden significantly.

The Ensemble Partnership — Why It Matters

In early 2026, Cohere Health and Ensemble Health Partners announced they are jointly building an RCM-native large language model — trained on real operational data from 30+ health systems. This isn't a GPT wrapper or prompt engineering exercise. It's a fine-tuned model built on Ensemble's scale (one of the largest RCM outsourcers in the country) and Cohere's clinical intelligence infrastructure.

The strategic implication is significant. Most healthcare AI vendors are competing on model access — who has the best API call to GPT-4 or Claude. The Ensemble-Cohere play shifts that competition to domain-specific training data. A model trained on millions of real RCM decisions, denial patterns, and auth outcomes will outperform a general-purpose LLM applied to the same problems — not because it's smarter, but because it knows the domain.

For health plans evaluating Cohere, this partnership is a signal: the company isn't standing pat as a prior auth tool. It's building toward a clinical AI layer that spans utilization management, coding, and denial logic — with one of the largest operational RCM datasets in the country behind it.

Recent Developments (2025–2026)

• $90M Series C (May 2025) — led by Temasek, bringing total funding to $200M. Capital earmarked for platform scaling, new clinical use cases, and AI product development.
• ZignaAI acquisition (September 2025) — entry into payment integrity; launched Cohere Validate, an AI-powered near-real-time clinical and coding validation tool.
• Cohere Align launch (March 2025) — provider-personalized PA workflows, replacing blunt gold carding with dynamic clinical risk stratification.
• Record 2025 growth (announced January 2026) — 10 new health plan deals closed, platform expanded into acute inpatient care and policy management.
• AHIP/CMS PA modernization initiative commendation (June 2025) — Cohere publicly supported the industry-wide pledge to accelerate PA reform, reinforcing their regulatory alignment positioning.

7 Powers Analysis

Bottom Line

← See all vendors in the RCM Vendor Deep Dive series

Published by RevCycleAI Research · April 2, 2026 · Sources: Cohere Health press releases, Geisinger Health Plan case study, CMS-0057-F final rule, AMA prior authorization survey 2024, Series C announcement (May 2025), ZignaAI acquisition announcement (September 2025), KLAS Research